{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T05:23:16Z","timestamp":1787030596044,"version":"build-2736575974"},"reference-count":46,"publisher":"The Journal of Rheumatology","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2021,5]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To compare disease characteristics, quality of life (QOL), and work productivity of patients with psoriatic arthritis (PsA) who had multidomain vs single-domain presentations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Adults with PsA enrolled in the Corrona PsA\/Spondyloarthritis Registry (March 2013\u2013August 2018) were included. Six PsA disease domains were evaluated: enthesitis, dactylitis, peripheral arthritis (PA), nail psoriasis, axial disease, and skin disease. Patients were classified as having multidomain (\u2265 2 domains) or single-domain disease presentations; biologic initiators were characterized separately. Linear regression models evaluated the association of multidomain presentations with disease characteristics, QOL, and work productivity vs single-domain presentations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 2617 patients with PsA, 1698 (64.9%) had multidomain presentations, 617 (23.6%) had single-domain presentations, and 302 (11.5%) had no active disease features. Of 354 biologic initiators, 289 (81.6%) had multidomain presentations, 45 (12.7%) had single-domain presentations, and 20 (5.6%) had no active disease features. Overall, the most common single-domain and multidomain presentations, respectively, were skin disease (12.7%) and PA + skin disease (11.7%). Multidomain presenters were more likely to have fibromyalgia, depression, anxiety, and prior biologic use than single-domain presenters. Multidomain presentations were associated with significantly worse patient and physician global assessments of disease activity, pain, and fatigue; Health Assessment Questionnaire\u2013Disability Index and EuroQol 5-dimension scores; and work productivity at enrollment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this US real-world cohort, most patients had multidomain disease presentations, which was associated with worse disease activity, QOL, and work productivity measures. This study highlights the heterogeneity of PsA and the importance of assessing all PsA domains for optimizing disease management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3899\/jrheum.200371","type":"journal-article","created":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T12:33:53Z","timestamp":1601555633000},"page":"698-706","source":"Crossref","is-referenced-by-count":24,"title":["Effect of Multidomain Disease Presentations on Patients With Psoriatic Arthritis in the Corrona Psoriatic Arthritis\/Spondyloarthritis Registry"],"prefix":"10.3899","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4639-0775","authenticated-orcid":false,"given":"Alexis","family":"Ogdie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Hur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Rebello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert R.","family":"McLean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blessing","family":"Dube","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghan","family":"Glynn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip J.","family":"Mease","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2020,10,1]]},"reference":[{"key":"2022062303401357000_48.5.698.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2015.07.003"},{"key":"2022062303401357000_48.5.698.2","first-page":"11","article-title":"Early treatment of psoriatic arthritis is associated with improved patient-reported outcomes: findings from the etanercept PRESTA trial","volume":"33","author":"Kirkham","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"2022062303401357000_48.5.698.3","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210242"},{"key":"2022062303401357000_48.5.698.4","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.rdc.2015.07.001","article-title":"The epidemiology of psoriatic arthritis","volume":"41","author":"Ogdie","year":"2015","journal-title":"Rheum Dis Clin North Am"},{"key":"2022062303401357000_48.5.698.5","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.jaad.2005.03.046","article-title":"Epidemiology of psoriatic arthritis in the population of the United States","volume":"53","author":"Gelfand","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"2022062303401357000_48.5.698.6","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jaad.2018.06.027","article-title":"Prevalence of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational and clinical studies","volume":"80","author":"Alinaghi","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"2022062303401357000_48.5.698.7","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/art.39573","article-title":"Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 treatment recommendations for psoriatic arthritis","volume":"68","author":"Coates","year":"2016","journal-title":"Arthritis Rheum"},{"key":"2022062303401357000_48.5.698.8","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217159"},{"key":"2022062303401357000_48.5.698.9","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/acr.23789","article-title":"Special article: 2018 American College of Rheumatology\/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis","volume":"71","author":"Singh","year":"2019","journal-title":"Arthritis Care Res"},{"key":"2022062303401357000_48.5.698.10","first-page":"597","article-title":"Performance of screening tools for psoriatic arthritis: a cross-sectional study in primary care","volume":"56","author":"Karreman","year":"2017","journal-title":"Rheumatology"},{"key":"2022062303401357000_48.5.698.11","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.semarthrit.2017.10.021","article-title":"Considerations for the definition of remission criteria in psoriatic arthritis","volume":"47","author":"Mease","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"2022062303401357000_48.5.698.12","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.140582"},{"key":"2022062303401357000_48.5.698.13","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1002\/acr.23249","article-title":"Clinical characteristics, disease activity, and patient-reported outcomes in psoriatic arthritis patients with dactylitis or enthesitis: results from the Corrona Psoriatic Arthritis\/Spondyloarthritis Registry","volume":"69","author":"Mease","year":"2017","journal-title":"Arthritis Care Res"},{"key":"2022062303401357000_48.5.698.14","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.171094"},{"key":"2022062303401357000_48.5.698.15","doi-asserted-by":"publisher","DOI":"10.1002\/art.21972"},{"key":"2022062303401357000_48.5.698.16","unstructured":"StataCorp. Stata Statistical Software Relsease 15. College Station, TX: StataCorp, LLC, 2017."},{"key":"2022062303401357000_48.5.698.17","first-page":"PMS22","article-title":"The economic burden of skin symptoms in psoriatic arthritis","volume":"S194","author":"Tillett","year":"2018","journal-title":"Value Health"},{"key":"2022062303401357000_48.5.698.18","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1007\/s10067-016-3319-5","article-title":"Psoriatic nail involvement and its relationship with distal interphalangeal joint disease","volume":"35","author":"Lai","year":"2016","journal-title":"Clin Rheumatol"},{"key":"2022062303401357000_48.5.698.19","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.ad.2015.02.005","article-title":"Nail psoriasis as a predictor of the development of psoriatic arthritis","volume":"106","author":"Raposo","year":"2015","journal-title":"Actas Dermosifiliogr"},{"key":"2022062303401357000_48.5.698.20","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keg217"},{"key":"2022062303401357000_48.5.698.21","doi-asserted-by":"publisher","DOI":"10.1136\/ard.62.1.68"},{"key":"2022062303401357000_48.5.698.22","doi-asserted-by":"publisher","DOI":"10.1002\/art.20335"},{"key":"2022062303401357000_48.5.698.23","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209709"},{"key":"2022062303401357000_48.5.698.24","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.032268"},{"key":"2022062303401357000_48.5.698.25","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203696"},{"key":"2022062303401357000_48.5.698.26","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1002\/art.40226","article-title":"Safety and efficacy of intravenous golimumab in patients with active psoriatic arthritis: results through week twenty-four of the GO-VIBRANT study","volume":"69","author":"Kavanaugh","year":"2017","journal-title":"Arthritis Rheum"},{"key":"2022062303401357000_48.5.698.27","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212687"},{"key":"2022062303401357000_48.5.698.28","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31429-0"},{"key":"2022062303401357000_48.5.698.29","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60594-2"},{"key":"2022062303401357000_48.5.698.30","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210724"},{"key":"2022062303401357000_48.5.698.31","doi-asserted-by":"publisher","DOI":"10.1002\/art.20967"},{"key":"2022062303401357000_48.5.698.32","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204655"},{"key":"2022062303401357000_48.5.698.33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412679"},{"key":"2022062303401357000_48.5.698.34","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13075-018-1551-x","article-title":"Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3)","volume":"20","author":"Nash","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"2022062303401357000_48.5.698.35","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30952-8"},{"key":"2022062303401357000_48.5.698.36","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c147"},{"key":"2022062303401357000_48.5.698.37","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.100069"},{"key":"2022062303401357000_48.5.698.38","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s13075-019-1831-0","article-title":"Ixekizumab and complete resolution of enthesitis and dactylitis: integrated analysis of two phase 3 randomized trials in psoriatic arthritis","volume":"21","author":"Gladman","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"2022062303401357000_48.5.698.39","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jaad.2017.08.029","article-title":"Adalimumab for nail psoriasis: efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial","volume":"78","author":"Elewski","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"2022062303401357000_48.5.698.40","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1111\/bjd.17351","article-title":"Effect of secukinumab on the clinical activity and disease burden of nail psoriasis: 32-week results from the randomized placebo-controlled TRANSFIGURE trial","volume":"181","author":"Reich","year":"2019","journal-title":"Br J Dermatol"},{"key":"2022062303401357000_48.5.698.41","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1056\/NEJMoa1512711","article-title":"Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis","volume":"375","author":"Gordon","year":"2016","journal-title":"N Engl J Med"},{"key":"2022062303401357000_48.5.698.42","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/jdv.14033","article-title":"Ixekizumab treatment improves fingernail psoriasis in patients with moderate-to-severe psoriasis: results from the randomized, controlled and open-label phases of UNCOVER-3","volume":"31","author":"van de Kerkhof","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2022062303401357000_48.5.698.43","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.11.041"},{"key":"2022062303401357000_48.5.698.44","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/jdv.14738","article-title":"Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE study","volume":"32","author":"Reich","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2022062303401357000_48.5.698.45","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-eular.2932"},{"key":"2022062303401357000_48.5.698.46","first-page":"1251","article-title":"New GRAPPA and EULAR recommendations for the management of psoriatic arthritis","volume":"56","author":"Coates","year":"2017","journal-title":"Rheumatology"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.200371","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,8]],"date-time":"2023-10-08T16:47:14Z","timestamp":1696783634000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.200371"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,1]]},"references-count":46,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,5,1]]},"published-print":{"date-parts":[[2021,5]]}},"alternative-id":["10.3899\/jrheum.200371"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.200371","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,1]]}}}